Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

AACR 2016 /
CD4 T-cell immunotherapy targeting MAGE-A3 is safe, and shows early clinical responses

16th - 20th Apr 2016

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 06.05.16
Views: 1828

Dr Yong-Chen William Lu - National Cancer Institute, Bethesda, USA

Dr Yong-Chen William Lu presents his results at AACR 2016 from a phase I study of using CD4 T cells in therapy.

Often described as 'helper T Cells', CD4 T cells used by Dr Lu helped safely target cancer cells in trial patients and stimulate anti-tumour responses.

For more on this, you can watch an interview with Dr Lu here, or read the associated news article here.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation